UVX as an Adjuvant in the Treatment of Fungal Keratitis

Treatment Clinical Trial

Official title:

UVX as an Adjuvant in the Treatment of Fungal Keratitis

Clinical Trial Details — Status: Active, not recruiting

Administrative data

• NCT number: NCT03138785
• Other study ID #: 32768
• Status: Active, not recruiting
• Phase: N/A
• First received: February 22, 2017
• Last updated: April 29, 2017
• Start date: January 1, 2015
• Est. completion date: July 1, 2017

Study information

• Verified date: April 2017
• Source: Farabi Eye Hospital
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

In this study, investigators want to find the effect of adjuvant collagen cross-linking in the treatment of fungal keratitis

Recruitment information / eligibility

• Status: Active, not recruiting
• Enrollment: 20
• Est. completion date: July 1, 2017
• Est. primary completion date: June 1, 2017
• Accepts healthy volunteers: No
• Gender: All
• Age group: N/A and older

Eligibility

Inclusion Criteria:

• fungal keratitis documented by culture or confocal scanning without any previous treatment

Exclusion Criteria:

• Previous treatment

• Thinning at presentation

• Perforation

• Associated with other microbial or viral keratitis

Related Conditions & MeSH terms

• Keratitis
• Treatment

Intervention

Drug:
• topical voriconazole / levofloxacin systemic itraconazole
starting topical voriconazole every hour tapering after 4 days , levofloxacin every 6 hours, Itraconazole 100mg /BD for 2 weeks

Radiation:
• CXL
30 min Riboflavin prescription to the cornea followed by 30 min UV-A radiation at 3mW/cm2 associated with Riboflavin administration

Locations

Country	Name	City	State
n/a

Sponsors (1)

Lead Sponsor	Collaborator
Farabi Eye Hospital

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	time of complete healing (days)	time to scar formation (days)	180 days